Fineline Cube

Follow:
14435 Articles
Boehringer Ingelheim's Nerandomilast Receives NMPA Review for IPF Treatment
CompanyDrug

Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment

QYuns Therapeutics' QX002N Meets Primary Endpoint in AS Phase III Study
CompanyDrug

QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study

Takeda's Takhzyro Receives EMA Approval for New Administration Form in HAE Patients
CompanyDrug

Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients

National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
Policy / Regulatory

National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details

Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
Company

Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology

Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China
CompanyDrug

Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China

Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand
CompanyDeals

Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand

Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution
CompanyDeals

Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution

CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment
CompanyDrug

CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment

Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform
CompanyMedical Device

Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform

AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech
CompanyDeals

AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech

Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines
CompanyDeals

Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines